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was no observed trend in patient characteristics for the PRs except 
that all had adenocarcinoma histology. The DCR (PR or stable disease 
[SD] ≥8 weeks) in the vandetanib 100, 200 and 300 mg/day arms were 
47.1%, 38.9% and 61.1%, respectively. The adverse event (AE) proﬁle 
was consistent with that observed in previous studies of vandetanib 
in NSCLC; the most common AEs were rash (53%), diarrhea (51%), 
hypertension (47%) and asymptomatic QTc prolongation (40%). There 
was one fatal case of interstitial lung disease, which was reported 8 
days after vandetanib 300 mg was discontinued because of PD. EGFR 
gene ampliﬁcation analysis revealed 4/12 patients were FISH positive 
(SD and PD, both n=2) and 8/12 were FISH negative (PR, n=1; SD, 
n=3; and PD, n=4). Tumors from 27 patients were evaluated for EGFR 
mutations: conﬁrmed mutation (n=1; exon 19 deletion [746–750]); con-
ﬁrmed no mutation (n=21); unconﬁrmed (n=5). The mutation-positive 
patient was a female non-smoker with FISH-positive adenocarcinoma 
and a best response of PD. Among the three PRs evaluated, two had no 
EGFR mutation and one had an unconﬁrmed result. Although patient 
numbers are small, baseline plasma VEGF levels (mean ± SE) appeared 
to be lower in patients who experienced clinical beneﬁt following van-
detanib treatment: PR (68.3 ± 40.4 pg/mL, n=6) and SD (50.5 ± 13.3 
pg/mL, n=16) versus PD (128 ± 39.5 pg/mL, n=23).
Conclusions: In Japanese patients with refractory NSCLC, vandetanib 
monotherapy (100–300 mg/day) demonstrated antitumor activity with 
an acceptable safety and tolerability proﬁle. The possible relationship 
between plasma VEGF levels and clinical outcome requires further 
investigation. 
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Background: Bevacizumab (Bv) in combination with carboplatin/pacl-
itaxel received FDA approval in October 2006 for improving response 
rates and survival in ﬁrst-line treatment of advanced NSCLC patients 
without brain metastases. Brain metastases were excluded based on 
a grade 3 intracerebral hemorrhage from a hepatocellular carcinoma 
brain metastasis in the original phase I study. Since NSCLC is the most 
common cause of brain metastases, a large fraction of patients who 
might beneﬁt from Bv have never been evaluated formally. We report 
here on the safety of Bv therapy in 24 subjects with NSCLC following 
local therapy for brain metastases.
Methods: Subjects were treated on protocols AVF3671g (ATLAS) or 
AVF3752g (PASSPORT): 
The ATLAS phase III study includes platinum based chemotherapy 
with Bv, followed by Bv ± erlotinib (E) to disease progression, for 
subjects with advanced or metastatic non-squamous NSCLC. Brain 
metastases subjects had to have completed whole brain radiotherapy 
(WBRT). 
The PASSPORT phase II study includes Bv combined with ﬁrst-line or 
second-line systemic therapy in subjects with non-squamous NSCLC 
with treated brain metastases. Treatment for Brain metastases included 
radiosurgery, neurosurgery or WBRT.
Demographic characteristics, baseline disease characteristics, prior 
treatment, and on-study treatment are summarized by study. The overall 
rate of CNS hemorrhage and exact 95% conﬁdence interval using the 
method of Blyth-Still-Casella are reported. 
Results: These results pertain to data collected on subjects enrolled 
from March 2006 to follow-up through January 2007.
STUDY ATLAS - AVF3671g PASSPORT - AVF3752g
N Total: 7 Total: 19
 Men: 5 Men: 12
 Women: 2 Women: 7
Median Age 60 64
ECOG Status ECOG 0: 4 ECOG 0: 7
 ECOG 1: 3 ECOG 1: 12
Prior Therapy for WBRT: 7 WBRT alone: 12
CNS Mets  WBRT w/Radiosurgery or
  Neurosurgery: 3
  Radiosurgery alone: 4
Treatment Line 1st Line: 7 1st Line: 9
  2nd Line: 10
Concomitant Med. for CNS Mets N/A 4 subjects
 
The mean number of Bv doses (15 mg/kg/q3w) in the 24 treated sub-
jects was 4 and the median was 3 (range 1-15). 2 subjects were never 
treated with Bv. 
There were no CNS hemorrhages reported on either study (95 % upper 
conﬁdence limit: 12.6%).
On ATLAS, no subjects experienced Grade 3/4 CNS events. One on-
study death due to disease progression occurred while the subject was 
on the study treatment follow-up period.
On PASSPORT, 2 subjects experienced new onset Grade 3 CNS events 
of seizures. One of these 2 subjects was not treated with Bv; the other 
had residual resolving hemorrhage at baseline prior to study treatment. 
Conclusions: These preliminary data are encouraging with respect 
to safe administration of bevacizumab to subjects with treated brain 
metastases in these two ongoing studies. It is anticipated that data on 40 
subjects will be available at presentation; additional follow-up and sub-
jects are necessary to more precisely characterize the CNS hemorrhage 
rate and overall safety of Bv treatment in this setting. 
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Vandetanib (ZACTIMA™; ZD6474) is a once-daily oral anticancer 
drug in Phase III clinical development in a broad population of patients 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS468
with advanced NSCLC. Vandetanib targets clinically validated signal-
ing pathways in NSCLC by inhibiting VEGFR-dependent tumor angio-
genesis and EGFR-dependent tumor growth and survival. Vandetanib 
also inhibits RET kinase activity, which is an important growth driver 
in certain types of thyroid cancer. 
Phase I evaluation in patients with advanced solid tumors showed 
vandetanib was generally well tolerated at daily oral doses of ≤300 mg. 
Common adverse events included rash, diarrhea and asymptomatic QTc 
prolongation, all of which were controlled by standard management. A 
series of randomized, double-blind Phase II studies have investigated 
the efﬁcacy of vandetanib in NSCLC, both as monotherapy and in 
combination with certain chemotherapies. A two-part study compared 
vandetanib (300 mg) with geﬁtinib (IRESSA™; 250 mg) in 2nd/3rd-
line NSCLC (in part B, eligible patients had the option to switch to 
the alternative treatment). The study achieved its primary efﬁcacy 
objective: median progression-free survival (PFS) in part A was 11 
weeks for vandetanib versus 8 weeks for geﬁtinib (HR=0.69, 95% CI 
= 0.50-0.96; 1-sided P=0.013). In 2nd-line NSCLC, vandetanib (100 
or 300 mg) or placebo was assessed in combination with docetaxel. 
This study also achieved its primary objective, with vandetanib 100 
mg + docetaxel demonstrating a signiﬁcant prolongation of PFS versus 
docetaxel alone (HR=0.64, 95% CI = 0.38-1.05; 1-sided P=0.037). In 
1st-line NSCLC, vandetanib (300 mg/day) ± carboplatin and paclitaxel 
(CP) was compared with CP + placebo. The primary objective was met, 
with vandetanib + CP prolonging PFS versus CP alone (HR=0.76, 95% 
CI = 0.50-1.15; 1-sided P=0.098): median PFS was 24 weeks (vande-
tanib + CP) and 23 weeks (CP). The vandetanib monotherapy arm was 
stopped early after a planned interim PFS analysis met the criterion 
for discontinuation (HR >1.33 vs CP). In all three studies, no overall 
survival beneﬁt with vandetanib was seen. However, overall survival 
was a secondary endpoint in these studies and the effect of vandetanib 
on survival is potentially confounded by the impact of post-progression 
therapies.
The positive outcomes from the Phase II studies have led to the initia-
tion of Phase III evaluation of vandetanib in a broad population of pa-
tients with advanced NSCLC, including squamous and non-squamous 
cell histology (Table). Clinical development is also ongoing in other 
tumor types, including hereditary medullary thyroid cancer, where 
encouraging antitumor activity has been observed.







Vandetanib versus placebo in patients previously treated with 
anti-EGFR therapy (6474IL0044) 300 Overall survival
Vandetanib versus erlotinib in refractory NSCLC (6474IL0057) 300 PFS
Combination regimens 
Vandetanib + docetaxel in 2nd-line NSCLC (6474IL0032) 100 PFS
Vandetanib + pemetrexed in 2nd-line NSCLC (6474IL0036) 100 PFS
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Background: PC administered in combination with bevacizumab 
extends survival for advanced non-squamous NSCLC pts. Based on 
SEER data, elderly pts (age ≥ 70 years) represent > 50% of all new 
cases of lung cancer and present unique therapeutic challenges. The 
ECOG 4599 database was analyzed to compare the outcomes in elderly 
pts treated with PCB vs. PC alone.
Methods: Pts ≥ 70 years at study entry constituted the elderly cohort. 
Each arm (PCB vs. PC) and age group (≥ 70 vs. < 70) was compared 
with respect to baseline pt characteristics, response rate (RR), progres-
sion-free survival (PFS), survival and toxicity.
Results: Out of 850 eligible pts, 26% (N=224) were ≥ 70 years of age 
(1.6% > 80 years). Median age for the elderly was 74 yrs; 44% were 
≥ 75 yrs. Baseline characteristics of the elderly cohort were similar to 
the younger group except for a higher proportion of males (62% vs. 
52%, P = 0.005). For the elderly pts, there was a trend towards superior 
response rate (29% vs. 17%, P = 0.067) and median PFS (5.9 mos vs. 
4.9 mos, P = 0.063) with PCB when compared to PC, though there was 
no difference in overall survival (PCB = 11.3 mos; PC = 12.1 mos; 
P=0.4). Grades 3-5 toxicities (CTC version 2.0) were noted in 87% of 
elderly pts treated with PCB compared to 61% with PC (P < 0.001). 
Treatment-related death rates with PCB vs. PC were 6.3% vs. 1.8% 
(NS) for the elderly. Febrile neutropenia (6% vs. 0.9%), proteinuria 
(8% vs. 0) and hypertension (6% vs. 0.9%) were more common with 
PCB than PC among the elderly. When compared to younger pts, the 
elderly experienced more neutropenia (34% vs. 22%), bleeding (7.9% 
vs. 3.2%), proteinuria (7.9% vs. 1.3%), muscle weakness (7.9% vs. 
2.2%) and motor neuropathy (3.5% vs. 0.6%) with PCB.
Conclusions: The proportion of elderly patients in ECOG 4599 is the 
highest recorded among ECOG phase III studies for advanced NSCLC. 
Increased toxicity with the addition of bevacizumab in those ≥ 70 yrs 
may have contributed to the absence of survival beneﬁt for PCB vs PC, 
but this observation is limited by its post-hoc, retrospective nature.
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